Organon (OGN) Long-Term Investments (2024)
Organon (OGN) posted quarterly Long-Term Investments of $1.0 million for Q4 2024.
Organon (OGN) Long-Term Investments (2024) Analysis & Trends
Organon has reported Long-Term Investments for 1 years, with the latest figure at $1.0 million in Q4 2024.
- Long-Term Investments for Q4 2024 came in at $1.0 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2024 was $1.0 million (changed N/A YoY), and the FY2024 annual result was $1.0 million, changed N/A from the prior year.
- Long-Term Investments steadied at $1.0 million in Q4 2024.
- Over five years, Long-Term Investments peaked at $1.0 million in Q4 2024 and troughed at $1.0 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 266.00 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 1.22 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 69.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 297.00 Mn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 1.56 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 135.51 Mn |
| 10 | Organon | 3.61 Bn | 2.48 Bn | 847.00 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1.00 Mn |